Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the presentation of new data further highlighting the efficacy and safety of VYVGART® (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and...
Latest News
ALKIVIA data demonstrate significant improvement in muscle strength and physical function in myositis patients treated with efgartigimod RHO data show efgartigimod achieved sustained reduction in autoantibodies and improved functional outcomes in patients with Sjogren’s disease; program granted U.S. FDA Fast Track designation argenx committed to new therapeutic areas in rheumatology...
AMSTERDAM, THE NETHERLANDS — Argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced topline results from the ADDRESS study evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with pemphigus vulgaris (PV) and pemphigus foliaceus (PF). The ADDRESS...
Amsterdam, Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that data from its Phase 3 ADHERE trial evaluating VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in patients with chronic inflammatory demyelinating polyneuropathy (CIDP)...
LA JOLLA, Calif. — Arialys Therapeutics, a clinical-stage biotechnology company pioneering new precision medicines for autoimmune neuropsychiatric diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to ART5803 for the treatment of pediatric patients with anti-NMDA receptor encephalitis (ANRE). ART5803 is a...
BERLIN, Germany — Ariceum Therapeutics (Ariceum), a targeted radiotherapeutics company dedicated to setting new standards in cancer care, today announced that the first patient has been dosed in the SANTANA-225 Phase 1/2 study of 225Ac-SSO110 for the treatment of extensive stage small cell lung cancer (ES-SCLC) and Merkle Cell Carcinoma...
BERLIN, Germany — Ariceum Therapeutics (Ariceum), a targeted radiotherapeutics company dedicated to setting new standards in cancer care, today highlighted two oral presentations showcasing the SANTANA-225 Phase 1/2 clinical trial design and preclinical data supporting 225Ac-SSO110’s differentiated profile as a targeted alpha radioligand therapy for somatostatin receptor 2 (SSTR2) positive...
BRIDGEWATER, N.J. – Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved ARIKAYCE®(amikacin liposome inhalation suspension) for the treatment of patients with nontuberculous mycobacterial (NTM)...
Tempe, AZ – The human brain is an incredibly adaptable organ, often able to heal itself even from significant trauma. Yet for the first time, new research shows even brief contact with a common herbicide can cause lasting damage to the brain, which may persist long after direct exposure ends....
Watertown, Mass. — Arkuda Therapeutics, a biotechnology company applying novel insights at the intersection of lysosomal biology and neuronal health to develop medicines that change the trajectory of neurodegenerative disease, announced Arkuda co-founder and previous Senior Vice President, Head of Discovery, Duane Burnett, PhD, has been appointed Chief Technology Officer,...